DRUG-SAFETY PROGRAM IMPACT AT HEALTH CARE PERCEPTION AT PATIENTS DIAGNOSED WITH PERSISTENT SEVERE ASTHMA.
Author(s)
Estrada JI1, Restrepo AM1, Giraldo PA1, Serna JA1, Abad JM2, Segura AM3
1+helPharma IPS, Medellin, Colombia, 2SURA EPS, Medellin, Colombia, 3CES University, Medellin, Colombia
OBJECTIVES:: determining the impact generated by a drug-safety program on the health care perception of the target population. METHODS:: a paired samples study was conducted (1 year before and after). The recruitment period was between May 2013 and June 2015 in Antioquia, Valle, Atlántico and Cundinamarca. The population was diagnosed with persistent severe asthma. They started a pharmacological treatment with Omalizumab and education courses every month from a pharmacist of the drug-safety program (post-test). This Education was focused on the appropriate medication usage and the importance of pharmacological adherence. The dependent variables were the patient’s proportion that improved their health care perception and their average of improvement. Absolute and relative frequencies were used, summary measures (central tendency, scatter and position). Normality tests were performed (Kolmogorov-Smirnov) and association tests (t-student paired y McNemar). The confidence interval was 95% and a standard 5% error was used. Asthma Control Test (ACT) survey was performed to measure the health care perception. A quantitative scale of 0-25 points was used, being 0 the worst score and 25 the best. In addition, a qualitative polytomic scale with the following categories: 0-19 "uncontrolled-asthma", 20-24 "well controlled-asthma" and 25 "fully controlled-asthma". RESULTS:: the evaluated population (n: 237) predominated for being adherent (85%), use correctly medication (90%), women (70%), adults (36 [IR 19-54] years old), workers (37%) or students (27%), with low schooling level (77% ≤ high school) and low socio-economical level (85% ≤ 3), of urban areas (95%) of Antioquia (91%). 70% of patients improved their health care perception. 57% cataloged as uncontrolled-asthma at baseline were switched to well controlled-asthma and 21% to fully controlled-asthma (p-value <0.000), they improved of an average from 17,5±5.5 to 22,1±2.7 (p-value <0.000). CONCLUSIONS:: ensuring the correct usage and sufficient adherence of Omalizumab improve the health care patients perception.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS12
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Respiratory-Related Disorders